Unknown

Dataset Information

0

Increased HDL cholesterol and apoA-I in humans and mice treated with a novel SR-BI inhibitor.


ABSTRACT: Increasing HDL levels is a potential strategy for the treatment of atherosclerosis.ITX5061, a molecule initially characterized as a p38 MAPK inhibitor, increased HDL-C levels by 20% in a human population of hypertriglyceridemic subjects with low HDL levels. ITX5061 also moderately increased apoA-I but did not affect VLDL/LDL cholesterol or plasma triglyceride concentrations. ITX5061 increased HDL-C in WT and human apoA-I transgenic mice, and kinetic experiments showed that ITX5061 decreased the fractional catabolic rate of HDL-CE and reduced its hepatic uptake. In transfected cells, ITX5061 inhibited SR-BI-dependent uptake of HDL-CE. Moreover, ITX5061 failed to increase HDL-C levels in SR-BI(-/-) mice. To assess effects on atherosclerosis, ITX5061 was given to atherogenic diet-fed Ldlr(+/-) mice with or without CETP expression for 18 weeks. In both the control and CETP-expressing groups, ITX5061-treated mice displayed reductions of early atherosclerotic lesions in the aortic arch -40%, P<0.05), and a nonsignificant trend to reduced lesion area in the proximal aorta.Our data indicate that ITX5061 increases HDL-C levels by inhibition of SR-BI activity. This suggests that pharmacological inhibition of SR-BI has the potential to raise HDL-C and apoA-I levels without adverse effects on VLDL/LDL cholesterol levels in humans.

SUBMITTER: Masson D 

PROVIDER: S-EPMC2783626 | biostudies-literature | 2009 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Increased HDL cholesterol and apoA-I in humans and mice treated with a novel SR-BI inhibitor.

Masson David D   Koseki Masahiro M   Ishibashi Minako M   Larson Christopher J CJ   Miller Stephen G SG   King Bernard D BD   Tall Alan R AR  

Arteriosclerosis, thrombosis, and vascular biology 20091008 12


<h4>Objective</h4>Increasing HDL levels is a potential strategy for the treatment of atherosclerosis.<h4>Methods and results</h4>ITX5061, a molecule initially characterized as a p38 MAPK inhibitor, increased HDL-C levels by 20% in a human population of hypertriglyceridemic subjects with low HDL levels. ITX5061 also moderately increased apoA-I but did not affect VLDL/LDL cholesterol or plasma triglyceride concentrations. ITX5061 increased HDL-C in WT and human apoA-I transgenic mice, and kinetic  ...[more]

Similar Datasets

| S-EPMC4479333 | biostudies-literature
| S-EPMC3220294 | biostudies-literature
| S-EPMC3495568 | biostudies-literature
| S-EPMC4188264 | biostudies-literature
| S-EPMC2724056 | biostudies-literature
| S-EPMC9141204 | biostudies-literature
| S-EPMC3065119 | biostudies-literature
| S-EPMC3307641 | biostudies-literature
| S-EPMC3276468 | biostudies-other
| S-EPMC4555973 | biostudies-literature